Jeffrey Nielsen | Vice President of Discovery
Eradivir, Inc.

Jeffrey Nielsen, Vice President of Discovery, Eradivir, Inc.

Dr. Jeffery Nielsen is vice president of discovery at Eradivir, overseeing the early discovery efforts for the pipeline of Eradivir. He has spent the last 11 years on early drug discovery and development. He is trained both as a chemist and a biologist using an interdisciplinary approach to design and discover next generation targeted therapeutics. Dr. Nielsen has successfully led R&D teams in academia at Brigham Young University, Max Planck Institute, and Purdue University and in industry at Biofire diagnostics, Novosteo and Quince therapeutics. Dr. Nielsen was part of an integral team that led to the translation of technology for Novosteo from discovery to acquisition by the publicly traded company Cortexyme. Two products he was part of the discovery team for are now FDA approved and marketed. Dr Nielsen has founded or co-founded 4 successful companies in 2 different industries.   He has published 26 peer reviewed journal articles and abstracts and is a primary inventor on 11 US patents/patents pending. Dr Nielsen has additionally presented at over 50 international and national scientific conferences and been awarded 38 academic and professional awards including the young investigator award from the American Society of Bone and Mineral Research. He earned a B.S. in Biochemistry and B.S. in Genetics and Biotechnology with a concentration in human disease from Brigham Young University and a PhD in Medicinal Chemistry and Molecular Pharmacology from Purdue University.


Day 2 - November 29 @ 15:30

Development of small bispecifc drugs targeting influenza and other respiratory diseases

last published: 02/Jan/24 12:15 GMT

back to speakers